Fresenius SE KGaA Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Sen

İcra Kurulu Başkanı

€4.7m

Toplam tazminat

CEO maaş yüzdesi	25.3%
CEO görev süresi	2.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	6.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Sen'un ücretlendirmesi Fresenius SE KGaA'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	€941m
Jun 30 2023	n/a	n/a	€1b
Mar 31 2023	n/a	n/a	€1b
Dec 31 2022	€5m	€1m	€1b
Sep 30 2022	n/a	n/a	€1b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	€2m	€755k	€2b

Tazminat ve Piyasa: Michael 'ın toplam tazminatı ($USD 5.10M ) BG pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 4.29M ).

Tazminat ve Kazançlar: Michael şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Michael Sen (55 yo)

2.8yrs

Görev süresi

€4,704,000

Tazminat

Mr. Michael Sen is Chairman of the Supervisory Board at Fresenius Medical Care AG & Co. KGaA from July 14, 2023. He is Chief Executive Officer & President - Fresenius Management SE at Fresenius SE & Co. KG...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Sen	CEO, President & Chairman of Management Board - Fresenius Management SE	2.8yrs	€4.70m	Veri yok
Sara Hennicken	CFO & Member of the Management Board - Fresenius Management SE	1.4yrs	€1.19m	Veri yok
Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	less than a year	Veri yok	Veri yok
Michael Moser	Member of Management Board of Fresenius Management SE	less than a year	Veri yok	Veri yok
Robert Moller	Member of the Management Board of Fresenius Management SE	less than a year	Veri yok	Veri yok
Markus Georgi	Senior Vice President of Investor Relations	8.8yrs	Veri yok	Veri yok
Matthias Link	Senior Vice President Corporate Communications	no data	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

49.5yo

Ortalama Yaş

Deneyimli Yönetim: FRE 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerd Krick	Honorary Chairman of Supervisory Board	2.8yrs	€219.00k	Veri yok
Michael Diekmann	Deputy Chairman of the Supervisory Board	8.8yrs	€320.00k	Veri yok
Wolfgang Kirsch	Chairman of Supervisory Board	2.8yrs	€540.00k	Veri yok
Konrad Kölbl	Member of Supervisory Board	16.6yrs	€220.00k	Veri yok
Grit Genster	Deputy Chairman of the Supervisory Board	4.1yrs	€310.00k	Veri yok
D. Albrecht	Member of Supervisory Board	13.1yrs	€180.00k	Veri yok
Iris Low-Friedrich	Member of Supervisory Board	7.8yrs	€180.00k	Veri yok
Susanne Zeidler	Member of the Supervisory Board	2yrs	€270.00k	Veri yok
Frauke Lehmann	Member of Supervisory Board	7.8yrs	€180.00k	Veri yok
Oscar De Paco	Member of Supervisory Board	7.8yrs	€180.00k	Veri yok
Bernd Behlert	Member of Supervisory Board	5.4yrs	€180.00k	Veri yok
Christoph Zindel	Member of Supervisory Board	1.8yrs	€139.00k	Veri yok

6.6yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FRE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).

Fresenius SE KGaA Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New minor risk - Profit margin trend

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş